Zhangjiagang First Peoples Hospital Zhangjiagang

Suzhou, China

Zhangjiagang First Peoples Hospital Zhangjiagang

Suzhou, China
SEARCH FILTERS
Time filter
Source Type

Wang S.,Zhangjiagang First Peoples Hospital Zhangjiagang | Tu J.,Zhangjiagang First Peoples Hospital Zhangjiagang | Zhou C.,Zhangjiagang First Peoples Hospital Zhangjiagang | Li J.,Zhangjiagang First Peoples Hospital Zhangjiagang | And 3 more authors.
Archives of Pharmacal Research | Year: 2014

Lfcin-B, an antimicrobial peptide found in various exocrine secretions of mammals, showed antitumor effects. However, the effect and relative mechanism of Lfcin-B on non-small cell lung cancer is unclear. In this study, assay of cell viability, quantitative real-time PCR, Western blot, annexin V/propidium iodide assay, flow cytometry and tumor-xenograft model were applied to elucidate the mechanism of Lfcin-B on non-small cell lung cancer NCI-H460 (H460) cells. Lfcin-B significantly suppressed the proliferation of H460 cells in vitro. Additionally, the transcription and translation of the VEGF gene in H460 cells were restrained after exposure to Lfcin-B. Moreover, the apoptosis of H460 cells was induced by Lfcin-B through stimulating caspase-3, caspase-9 and preventing survivin expression on both the transcription and translation level. Meanwhile, Lfcin-B increased the production of reactive oxygen species and suppressed the RNA of antioxidant enzymes (GPX1, GPX2, SOD3 and catalase) in H460 cells. Finally, Lfcin-B significantly prevented the tumor growth in the H460-bearing mice model. These results indicated that Lfcin-B could be a potential candidate for the treatment of lung cancer. © 2014 The Pharmaceutical Society of Korea.


Wang S.,Zhangjiagang First Peoples Hospital Zhangjiagang | Tu J.,Zhangjiagang First Peoples Hospital Zhangjiagang | Zhou C.,Zhangjiagang First Peoples Hospital Zhangjiagang | Li J.,Zhangjiagang First Peoples Hospital Zhangjiagang | And 3 more authors.
Archives of pharmacal research | Year: 2015

Lfcin-B, an antimicrobial peptide found in various exocrine secretions of mammals, showed antitumor effects. However, the effect and relative mechanism of Lfcin-B on non-small cell lung cancer is unclear. In this study, assay of cell viability, quantitative real-time PCR, Western blot, annexin V/propidium iodide assay, flow cytometry and tumor-xenograft model were applied to elucidate the mechanism of Lfcin-B on non-small cell lung cancer NCI-H460 (H460) cells. Lfcin-B significantly suppressed the proliferation of H460 cells in vitro. Additionally, the transcription and translation of the VEGF gene in H460 cells were restrained after exposure to Lfcin-B. Moreover, the apoptosis of H460 cells was induced by Lfcin-B through stimulating caspase-3, caspase-9 and preventing survivin expression on both the transcription and translation level. Meanwhile, Lfcin-B increased the production of reactive oxygen species and suppressed the RNA of antioxidant enzymes (GPX1, GPX2, SOD3 and catalase) in H460 cells. Finally, Lfcin-B significantly prevented the tumor growth in the H460-bearing mice model. These results indicated that Lfcin-B could be a potential candidate for the treatment of lung cancer.

Loading Zhangjiagang First Peoples Hospital Zhangjiagang collaborators
Loading Zhangjiagang First Peoples Hospital Zhangjiagang collaborators